Vivos Is Pivoting to Another Capital Raise: Why the Rights Offering Matters More Than the Hype

The rights offering points to continued funding needs

Vivos is not celebrating a finished cycle; it is moving toward another equity raise. The company says it intends to file a registration statement for a proposed rights offering, then distribute transferable subscription rights as a dividend after the SEC declares the filing effective. The record date would be 30 days after effectiveness, the rights would be exercisable for nine months, and the exercise price would be the greater of $1.25 or 20% above the day-before-market price. Those are real dilution mechanics, not marketing language SEC-effectiveness-dependent rights offering terms.

The cash-flow pattern matters more than the headlines

Look at the financing history. Vivos raised $24.15 million in gross proceeds at its IPO IPO gross proceeds. Earlier this year, it closed a warrant exercise for about $4.64 million warrant exercise gross proceeds. In 2024, another warrant transaction added roughly $4.0 million 2024 warrant gross proceeds.

Bulls can frame the rights offering as a cleaner way to extend runway by giving existing holders first access. Bears will focus on the simpler signal: repeated equity events usually mean the business still needs cash before commercialization is self-funding.

The core point is this: the product narrative can be compelling, but the shareholder-value story depends on whether Vivos can fund that growth without another series of equity and warrant transactions.

Why Vivos may need more capital before commercialization proves out

The bull case works only if capital lasts long enough for adoption to build. That is why this rights offering matters. Vivos is selling a large market story, with OSA affecting over 1 billion people worldwide and many cases still undiagnosed. It also has a tangible product wedge: the CARE platform includes devices FDA-cleared for adult mild-to-severe OSA and moderate-to-severe pediatric OSA.

Still, commercialization usually spends money before it reliably returns it. Provider education, case generation, and working capital can all be necessary while treatment volume scales.

Recent financing was tied to day-to-day operations

If Vivos were already generating enough cash from scaled treatment volume, another capital call would look less urgent. The evidence here points the other way. Earlier this year, management said warrant-exercise proceeds would be used for working capital and general corporate purposes, and it issued new unregistered warrants to buy 3,964,712 shares as part of that transaction.

That matters because it suggests the company was supporting routine operations, not simply wrapping up a financing event.

The market story is real, but timing is still the pressure point

The opportunity is real, but the balance sheet still looks like the bottleneck. A big market does not by itself pay for sales coverage, inventory, or the cash cycle required to move patients from diagnosis to treatment.

The March 2026 Settlement Agreement with Ortho-Tain is not the main thesis, but it can still matter as an execution overhang while management is trying to build confidence with investors. For now, the key question is whether this rights offering extends runway long enough for commercialization to start producing more of its own cash.

Watch three signals: - Whether management ties the raise to adoption drivers, not just survival - Whether existing holders actually participate - Whether execution stays clean while the settlement-related corrective statement period is still in effect

What to watch in the next phase of VVOS

This is now an execution trade

The next move is not about better marketing. It is about whether management can navigate SEC effectiveness timing, secure meaningful participation, and show that commercial demand is strong enough to justify another equity event. If that sequence works, the market may be able to look past dilution. If it falters, the stock becomes more of a capital-structure problem than a growth story.

Transferable rights change the dynamic

The practical setup is straightforward: Vivos plans to distribute transferable subscription rights as a dividend, with the record date set 30 days after effectiveness. Because the rights would be transferable, holders can sell them instead of exercising. And the pricing is not symbolic. The exercise price would be the greater of $1.25 or 20% above market, so participation has to be real.

If existing holders do not participate, the company still needs outside buyers, and that is when dilution can become more pronounced.

Story assets do not settle a financing decision

Yes, Vivos says OSA affects over 1 billion people worldwide. Yes, the company markets FDA-cleared CARE devices. But those are business-thesis assets, not proof that this financing event is low-risk.

The bear case is simple: this is another capital call after recent financing tied to working capital and general corporate purposes, alongside the distraction of the March 2026 Settlement Agreement with Ortho-Tain.

The stronger bull rebuttal is also straightforward: a rights offering only works if investors believe the current runway is a bridge to revenue, not the start of another string of equity events.

Practical watchpoints

• Bullish read: SEC effectiveness arrives on schedule, holders exercise rather than sell rights, and management links the capital raise directly to commercial scaling.
• Bearish read: The SEC timeline slips, rights trade heavily, or participation is weak.
• Investor posture: This looks more suitable for investors who want commercial upside and can accept dilution risk, and less suitable for those who want operating proof before more equity action.